Abstract
Apolipoprotein E (ApoE) plays a vital role in cholesterol metabolism and its allele polymorphisms have been associated with several diseases including Alzheimer’s disease (AD). There are few systematic studies on ApoE polymorphism and its association with AD in Chinese population. To examine this issue, participants included 4251 subjects and 404 AD patients with 390 healthy elderly residing in Chongqing city were genotyped. The results showed that the ε3 allele presented the highest frequency (82%), followed by ε4 (6.25%) and ε2 (11.75%) in general population. ε3/ε3 genotype carriers are the most common ones (64.19%) and the ε4/ε4 had the lowest frequency (0.59%). The frequency of ApoEε4 allele frequency in AD (15.35%) was significantly higher than control (10.00%). Those carriers of two ε4 allele have five time higher risk to develop AD. Our study demonstrate that ApoEε4 allele is a risk factor of AD for Chinese population.
Keywords: Alzheimer’s disease, polipoprotein E, China, enotype, olymorphism, opulation.
Current Alzheimer Research
Title:Association of Apolipoprotein E (ApoE) Polymorphism with Alzheimer's Disease in Chinese Population
Volume: 13 Issue: 8
Author(s): Lingling Zheng, Jianzhong Duan, Xiaoling Duan, Weitao Zhou, Chunjiang Chen, Yanhua Li, Jie Chen, Weihui Zhou, Yan-Jiang Wang, Tingyu Li and Weihong Song
Affiliation:
Keywords: Alzheimer’s disease, polipoprotein E, China, enotype, olymorphism, opulation.
Abstract: Apolipoprotein E (ApoE) plays a vital role in cholesterol metabolism and its allele polymorphisms have been associated with several diseases including Alzheimer’s disease (AD). There are few systematic studies on ApoE polymorphism and its association with AD in Chinese population. To examine this issue, participants included 4251 subjects and 404 AD patients with 390 healthy elderly residing in Chongqing city were genotyped. The results showed that the ε3 allele presented the highest frequency (82%), followed by ε4 (6.25%) and ε2 (11.75%) in general population. ε3/ε3 genotype carriers are the most common ones (64.19%) and the ε4/ε4 had the lowest frequency (0.59%). The frequency of ApoEε4 allele frequency in AD (15.35%) was significantly higher than control (10.00%). Those carriers of two ε4 allele have five time higher risk to develop AD. Our study demonstrate that ApoEε4 allele is a risk factor of AD for Chinese population.
Export Options
About this article
Cite this article as:
Zheng Lingling, Duan Jianzhong, Duan Xiaoling, Zhou Weitao, Chen Chunjiang, Li Yanhua, Chen Jie, Zhou Weihui, Wang Yan-Jiang, Li Tingyu and Song Weihong, Association of Apolipoprotein E (ApoE) Polymorphism with Alzheimer's Disease in Chinese Population, Current Alzheimer Research 2016; 13 (8) . https://dx.doi.org/10.2174/1567205013666160401115307
DOI https://dx.doi.org/10.2174/1567205013666160401115307 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Chemical and Biological Properties of Phenolics in Wine: Analytical Determinations and Health Benefits
Current Organic Chemistry Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Anti-Cancer, Pharmacokinetic and Biodistribution Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Non-invasive Atherosclerosis Imaging: Use to Assess Response to Novel or Combination Lipid Therapies
Current Drug Targets - Cardiovascular & Hematological Disorders Diadenosine Polyphosphates: Postulated Mechanisms Mediating the Cardiac Effects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Mutations of Nuclear and Mitochondrial Genomes as Potential Targets for the Treatment of Metabolic Syndrome
Current Pharmaceutical Design